Shots:

• Janssen to get exclusive WW license rights to develop & commercialize certain clinical candidates in MeiraGTx’s inherited retinal disease pipeline. Janssen also has an option to license the portfolio of products for gene targeting in inherited retinal disease- will be developed in collaboration with MeiraGTx
• The focus of the collaboration is to develop adeno-associated virus (AAV) technology exploring targets for delivering treatments in inherited retinal diseases including achromatopsia (ACHM) caused by mutations in CNGB3 or CNGA3 and X-linked retinitis pigmentosa (XLRP)
• AAV-CNGB3 and AAV-CNGA3 are gene therapy candidates administered via subretinal IV in the eye. AAV-CNGB3 has also received FDA’s ODD & FT designation for achromatopsia caused by mutations in the CNGB3 gene- evaluated in P-I/II in adults and pediatrics

  Ref: Janssen | Image: Janssen